公开(公告)号：KR1020130043995A

公开(公告)日：2013-05-02

申请号：KR1020110108222

申请日：2011-10-21

Applicant: 한국해양과학기술원

Inventor： 임정한 ,  김일찬 ,  김덕규 ,  한세종 ,  이형석 ,  오현철 ,  표석능

IPC: A61K31/553 ,  A61K31/551 ,  A61P9/10 ,  A61P9/00

CPC classification number: A61K31/395 ,  A23L7/109 ,  A23L33/105 ,  A23V2002/00 ,  A61K9/146 ,  A61K36/09 ,  A23V2200/326 ,  A23V2250/20

Abstract: PURPOSE: A composition for the prevention and treatment of arteriosclerosis containing a novel compound of stereocalpin-A is provided to suppress the expression of VCAM-1 and ICAM-1 induced by TNF-alpha due to the incapability of signal transduction to MAP kinse, Akt, and NF-kB by the suppression of the ROS production. CONSTITUTION: A pharmaceutical composition for the prevention and treatment of arteriosclerosis comprises stereocalpin-A represented by chemical formula 1 as an active ingredient. The stereocalpin-A represented by the chemical formula 1 is contained at 0.01-10 parts by weight based on 100 parts by weight of composition. The stereocalpin-A represented by chemical formula 1 suppresses the expression of cell adhesion molecules which induces the TNF-alpha. The cell adhesion molecules are ICAM-1 or VCAM-1. The stereocalpin-A is originated from Ramalina terebrata.

Abstract translation: 目的：提供一种用于预防和治疗动脉硬化的组合物，其中含有立体异构体-A的新型化合物，以抑制由于MAP kinse，Akt信号转导不能引起的TNF-α诱导的VCAM-1和ICAM-1的表达 ，NF-kB通过抑制ROS产生。 构成：用于预防和治疗动脉硬化的药物组合物包含由化学式1表示的立体偶联蛋白-A作为活性成分。 由化学式1表示的立体连接-A以相对于100重量份组合物计为0.01-10重量份。 由化学式1表示的立体连接蛋白-A抑制诱导TNF-α的细胞粘附分子的表达。 细胞粘附分子是ICAM-1或VCAM-1。 立体定位-A起源于Ramalina terebrata。